Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 12:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 696 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Activity Liking Clear all
Completed Not applicable Interventional Accepts healthy volunteers

A Multidimensional Behavioral Intervention for Those at Risk for Alzheimer's Dementia

NCT03549078
View directory record Official record
Conditions
Functional Aging, Subjective Cognitive Concerns, Compensation Strategies, Brain Health Activities
Interventions
Intervention
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
65 Years and older
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2020 · Synced Sep 7, 2026, 12:32 AM EDT
Withdrawn Not applicable Interventional

Transcranial Direct Current Stimulation and Cognitive Remediation Therapy for Interictal Dysfunction in Epilepsy

NCT02950506
View directory record Official record
Conditions
Epilepsy
Interventions
transcranial direct current stimulation, Cognitive Remediation Therapy
Device · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Saint Louis Park, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 17, 2022 · Synced Sep 7, 2026, 12:32 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.

NCT07003984
View directory record Official record
Conditions
Chikungunya Virus
Interventions
CHIKV VLP vaccine, Placebo
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
1 Year to 11 Years
Enrollment
720 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
8
States / cities
Fountain Valley, California • Washington D.C., District of Columbia • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Sep 7, 2026, 12:32 AM EDT
Completed Not applicable Interventional

Improving Brief Marijuana Interventions With a Behavioral Economic Supplement

NCT02837315
View directory record Official record
Conditions
Marijuana Use
Interventions
Brief Motivational Intervention (BMI), Substance-Free Activity Session (SFAS), Relaxation Session
Behavioral
Lead sponsor
University of Memphis
Other
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Sep 7, 2026, 12:32 AM EDT
Terminated Phase 3 Interventional Results available

A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises

NCT04927247
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Crisis, Vaso-occlusive Pain Episode in Sickle Cell Disease
Interventions
Inclacumab, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
17
States / cities
Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Sep 7, 2026, 12:32 AM EDT
Completed Phase 4 Interventional Results available

Effects of SGLT-2 Inhibition on Myocardial Fibrosis and Inflammation as Assessed by Cardiac MRI in Patients With DM2

NCT03782259
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Myocardial Fibrosis, Myocardial Inflammation
Interventions
dapagliflozin, Placebo
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced Sep 7, 2026, 12:32 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

NCT06052059
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
IV Tulisokibart, IV Placebo, SC Tulisokibart, SC Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years to 80 Years
Enrollment
1,020 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
76
States / cities
Dothan, Alabama • Fairhope, Alabama • Litchfield Park, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 7, 2026, 12:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Mental Health and School Performance in Urban Eighth Graders

NCT03906682
View directory record Official record
Conditions
Depressive Symptoms, Trauma, Psychological, Disruptive Behavior
Interventions
RAP Club, Healthy Topics
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
Not listed
Enrollment
615 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Sep 7, 2026, 12:32 AM EDT
Recruiting Phase 1 Interventional

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

NCT06501196
View directory record Official record
Conditions
Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Preleukemia, Myelodysplastic Syndromes, Refractory Acute Myeloid Leukemia
Interventions
BH-30236, Venetoclax
Drug
Lead sponsor
BlossomHill Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
13
States / cities
Duarte, California • Los Angeles, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Sep 7, 2026, 12:32 AM EDT
Completed No phase listed Observational

Wearable Sensors and Artificial Intelligence for Carbohydrate Counting

NCT05335889
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
eButton, Continuous Glucose Monitoring (CGM)
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 99 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Sep 7, 2026, 12:32 AM EDT
Terminated Phase 3 Interventional

The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis

NCT04985968
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Cobitolimod 250 mg, Cobitolimod 500 mg, Placebo
Drug
Lead sponsor
InDex Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
25
States / cities
Granada Hills, California • Mission Viejo, California • Rancho Cucamonga, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Sep 7, 2026, 12:32 AM EDT
Not listed Not applicable Interventional

rTMS and Rehabilitation for Individuals With CRPS Type 1

NCT05745025
View directory record Official record
Conditions
Complex Regional Pain Syndrome Type I
Interventions
Repeated Transcranial Magnetic Stimulation, Sham Repeated Transcranial Magnetic Stimulation, Rehabilitation
Device · Other
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Sep 7, 2026, 12:32 AM EDT
Completed Phase 1 Interventional

Training Executive, Attention and Motor Skills (TEAMS): Preliminary Studies

NCT01073176
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
TEAMS (Training Attention Executive and Motor Skills)
Other
Lead sponsor
Queens College, The City University of New York
Other
Eligibility
4 Years to 5 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Flushing, New York
Source: ClinicalTrials.gov public record
Updated Sep 13, 2011 · Synced Sep 7, 2026, 12:32 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of a Hospital Walking Program for Older Adults

NCT00715962
View directory record Official record
Conditions
Acute Disease
Interventions
Behavioral intervention, Walking Intervention, Friendly visits
Behavioral · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
65 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 23, 2016 · Synced Sep 7, 2026, 12:32 AM EDT
Completed Phase 4 Interventional Results available

A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)

NCT05564039
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Tirzepatide, Dulaglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
11
States / cities
Cooper City, Florida • West Palm Beach, Florida • Skokie, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced Sep 7, 2026, 12:32 AM EDT
Recruiting No phase listed Observational

Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists

NCT07702461
View directory record Official record
Conditions
Obesity & Overweight, Diabetes (DM)
Interventions
Glucagon-Like Peptide-1 Agonist (GLP-1)
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 7, 2026, 12:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluation and Treatment of Pulmonary Vascular Disease in Moderate to Severe CF

NCT02626182
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
sildenafil, placebo
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Sep 7, 2026, 12:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Diet Composition, Weight Control, and Breast Carcinogenesis

NCT01315483
View directory record Official record
Conditions
Breast Cancer
Interventions
Weight Loss Dietary Pattern
Other
Lead sponsor
Colorado State University
Other
Eligibility
21 Years and older · Female only
Enrollment
259 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 14, 2013 · Synced Sep 7, 2026, 12:32 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

NCT02787551
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin glargine/lixisenatide fixed ratio combination, liraglutide, exenatide, exenatide extended-release, albiglutide, dulaglutide, Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
74
States / cities
Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Sep 7, 2026, 12:32 AM EDT
Completed Not applicable Interventional

Pilot Study of Mothers and Babies Online in Home Visiting

NCT05714956
View directory record Official record
Conditions
Perinatal Depression
Interventions
Mothers and Babies Online (eMB)
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
16 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
Chicago, Illinois • Joliet, Illinois • Chariton, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Sep 7, 2026, 12:32 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Human Behaviors Related to the Expectation of Pain

NCT03739645
View directory record Official record
Conditions
Fear Pain
Interventions
Skin conductance levels and slopes over time in conditioned fear as metrics.as metrics for anxiety
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
16 Years to 88 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Sep 7, 2026, 12:32 AM EDT
Suspended Phase 1Phase 2 Interventional

Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1

NCT06071767
View directory record Official record
Conditions
HIV-1-infection
Interventions
ChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62, MVA.tHIVconsv3, MVA.tHIVconsv4, Vesatolimod (VES), GS-5423, GS-2872, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
9
States / cities
San Diego, California • Atlanta, Georgia • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 7, 2026, 12:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

PASOS: Improving the Health of Immigrant Workers

NCT02480244
View directory record Official record
Conditions
Overweight and Obesity, Diabetes
Interventions
Behavioral Intervention, Control
Behavioral · Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
554 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Oxnard, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Sep 7, 2026, 12:32 AM EDT
Completed Phase 2 Interventional

R33: Levetiracetam in Early Psychosis

NCT04317807
View directory record Official record
Conditions
Early Psychosis
Interventions
Levetiracetam Pill, Placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
16 Years to 40 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 7, 2026, 12:32 AM EDT